In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
COVID-19 and Cardiology Read more

Complete revascularisation is superior to culprit-lesion only intervention

COMPLETE trial presented in a Hot Line Session today at ESC Congress 2019 together with WCC

Interventional Cardiology and Cardiovascular Surgery
ST-Elevation Myocardial Infarction (STEMI)


Paris, France – 1 Sept 2019: An international randomised trial has shown that complete revascularisation reduces major cardiovascular events compared to culprit-lesion only percutaneous coronary intervention (PCI). Late breaking results of the COMPLETE trial are presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology (1) and published in the New England Journal of Medicine (2).

Up to 50% of patients with ST-segment elevation myocardial infarction (STEMI) have multivessel coronary artery disease. This means that in addition to the blocked artery that caused the heart attack (known as the culprit artery), they have additional narrowed arteries (called non-culprit) supplying blood to the heart.

In STEMI patients, opening the culprit artery with PCI reduces cardiovascular death or myocardial infarction. It is unclear whether additional PCI of non-culprit lesions also prevents these events.

“The question of whether to routinely revascularise non-culprit lesions or manage them conservatively with guideline-directed medical therapy alone is a common dilemma,” said principal investigator Professor Shamir R. Mehta of the Population Health Research Institute, McMaster University, Hamilton, Canada.

Observational studies suggest a reduction in clinical events with staged, non-culprit lesion PCI, but are limited by selection bias and confounding. Prior randomised trials found declines in composite outcomes with non-culprit lesion PCI but were not powered to detect improvements in hard, irreversible clinical outcomes such as cardiovascular death or new myocardial infarction. While meta-analyses indicate a decline in cardiovascular death or myocardial infarction with non-culprit lesion PCI, there has been no single, large trial showing benefit on this clinically important outcome. The COMPLETE trial was designed to address this evidence gap.

A total of 4,041 patients with STEMI and multivessel coronary artery disease were enrolled from 140 centres in 31 countries. Patients were randomly allocated to complete revascularisation with additional PCI of angiographically significant non-culprit lesions, or to no further revascularisation. Randomisation was stratified by the intended timing of non-culprit lesion PCI: either during or after the index hospitalisation.

The first co-primary outcome was the composite of cardiovascular death or myocardial infarction; the second co-primary outcome also included ischaemia-driven revascularisation.

At a median follow-up of three years, the first co-primary outcome of cardiovascular death or myocardial infarction occurred in 158 patients (7.8%) in the complete revascularisation group compared to 213 (10.5%) in the culprit-lesion only group (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.60–0.91; p=0.004).

The second co-primary outcome of cardiovascular death, myocardial infarction, or ischaemia-driven revascularisation occurred in 179 patients (8.9%) in the complete revascularisation group compared to 399 (16.7%) in the culprit-lesion only group (HR 0.51; 95% CI 0.43–0.61; p<0.001).

There were no significant differences between groups in the occurrence of stroke (p=0.27) or major bleeding (p=0.15).

Regarding the timing of non-culprit lesion PCI, complete revascularisation consistently reduced the first co-primary outcome in those stratified to receive non-culprit lesion PCI during the index hospitalisation (HR 0.77; 95% CI 0.59–1.00) and after hospital discharge (HR 0.69; 95% CI 0.49–0.97; interaction p=0.62).

Prof Mehta said: “COMPLETE is the first randomised trial to show that complete revascularisation reduces hard cardiovascular events compared to culprit-lesion only PCI in patients with STEMI and multivessel coronary artery disease. The benefits emerged over the long term and were observed regardless of whether non-culprit lesion PCI was performed early, during the initial hospitalisation or shortly after hospital discharge. These findings are likely to have a large impact on clinical practice and prevent many thousands of recurrent heart attacks globally every year.”

ENDS

Notes to editor

Notes to editors

Authors: ESC Press Office 
Mobile: +33 (0) 7 8531 2036
Email: press@escardio.org

Follow us on Twitter @ESCardioNews 

The hashtag for ESC Congress 2019 together with the World Congress of Cardiology is #ESCCongress

Funding: Canadian Institutes of Health Research, AstraZeneca, Boston Scientific.

Disclosures: Research grants AstraZeneca and Boston Scientific.

References and notes

(1) COMPLETE will be discussed during:

(2) The full paper will be available during Congress from press@escardio.org.

About ESC Congress

ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2019 together with the World Congress of Cardiology takes place from 31 August to 4 September at the Expo Porte de Versailles in Paris, France. Explore the scientific programme.

About the European Society of Cardiology 

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

This press release accompanies both a presentation and an ESC press conference at ESC Congress 2019 together with the World Congress of Cardiology. It does not necessarily reflect the opinion of the European Society of Cardiology.